Oncology News | pharmaphorum

News

ASCO26: Ivonescimab improves survival in NSCLC

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

News

ASCO26: BMS hails "compelling" phase 3 celmod readout

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.

News

Ahead of ASCO data drop, AZ gets key Imfinzi approval

AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News

AbbVie's Immunogen buy delivers rare cancer drug approval

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

ASCO26: Ivonescimab improves survival in NSCLC

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

ASCO26: BMS hails "compelling" phase 3 celmod readout

Ahead of ASCO data drop, AZ gets key Imfinzi approval

Innovent in line for $10.5bn in Pfizer cancer alliance

AbbVie's Immunogen buy delivers rare cancer drug approval

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks